`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`MYLAN PHARMACEUTICALS INC.,
`
`Petitioner,
`v.
`
`SANOFI-AVENTIS DEUTSCHLAND GMBH,
`
`Patent Owner.
`
`————————————————
`Case No. IPR2018-01670 - Patent No. 8,679,069
`Case No. IPR2018-01675 - Patent No. 8,603,044
`Case No. IPR2018-01676 - Patent No. 8,603,044
`Case No. IPR2018-01678 - Patent No. 8,992,486
`Case No. IPR2018-01679 - Patent No. 8,992,486
`Case No. IPR2018-01680 - Patent No. 9,526,844
`Case No. IPR2018-01682 - Patent No. 9,526,844
`Case No. IPR2018-01684 - Patent No. 9,604,008
`Case No. IPR2018-01696 - Patent No. 9,526,844
`Case No. IPR2019-00122 - Patent No. 8,992,486
`_____________________________
`
`DECLARATION OF ELHAM F. STEINER IN SUPPORT OF
`PETITIONER’S MOTION FOR PRO HAC VICE ADMISSION
`
`
`
`
`
`
`
`
`
`
`
`
`Mylan Exhibit - 1040
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`I, Elham F. Steiner, hereby declare the following:
`
`1.
`
`I am a member in good standing of the state bars of New York and
`
`California, of the United States Court of Appeals for the Federal Circuit, and of
`
`numerous United States District Courts.
`
`2.
`
`I have not been suspended or disbarred from practice before any court
`
`or administrative body.
`
`3.
`
`No court or administrative body has denied my application for
`
`admission.
`
`4.
`
`No court or administrative body has imposed sanctions or contempt
`
`citations imposed on me.
`
`5.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide (and update) and the Board’s Rules of Practice for Trials set forth in 37 CFR
`
`part 42.
`
`6.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§11.101 et. seq. and to disciplinary jurisdiction under 37 C.F.R.
`
`§11.19(a).
`
`7. Within the last three years, I have appeared pro hac vice in only the
`
`following proceeding before the Board: Mylan Technologies, Inc. v. MonoSol RX,
`
`LLC (IPR2017-00200) and related proceedings for Mylan Pharmaceuticals Inc. v.
`
`Sanofi-Aventis Deutschland GmbH (IPR2017-01526 and IPR2017-01528).
`
`1
`
`Mylan Exhibit - 1040
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`8.
`
`I am counsel for Mylan Pharmaceuticals Inc. in the related district
`
`court litigation with Sanofi-Aventis in the District of New Jersey. As a result, I
`
`have particular experience and familiarity with the substantive and technical issues
`
`involved in these proceedings from that representation, and from coordination in
`
`these proceedings.
`
`9.
`
`I am a patent litigation attorney with experience representing clients in
`
`multiple jurisdictions, including United States District Courts and the Federal
`
`Circuit Court of Appeals. I have experience in all stages of litigation, from
`
`preliminary injunction through trial and appeal, and across a wide range of
`
`technologies, including pharmaceutical-related technologies. My pertinent
`
`biographical background appears in Exhibit 1041.
`
`10.
`
`I have reviewed in detail U.S. Patent Nos. 8,679,069; 8,603,044;
`
`8,992,486; 9,526,844 and 9,604,008, and the parties’ submissions in the present
`
`proceedings.
`
`11.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true; and further that these statements are made with the knowledge
`
`that willful false statements and the like so made are punishable by fine or
`
`imprisonment, or both, under Section 1001 of Title 18 of the United States Code.
`
`2
`
`Mylan Exhibit - 1040
`Mylan v. Sanofi - IPR2018-01676
`
`
`
`
`
`Dated: February 27, 2019
`
`
`
`c,e_.,__
`
`
`Elham F. Steiner
`
`3
`
`Mylan Exhibit - 1040
`Mylan v. Sanofi - IPR2018-01676
`
`